Home > Insider Trading > Filing (0001062993-23-018542)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1444192	Acasti Pharma Inc.	ACST	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1697184	Vimal Kavuru	C/O Acasti Pharma Inc. 2572 Boul. Daniel-Johnson, 2Nd Floor Laval A8 H7T 2R3		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Acquisiton	2023-09-25	676,371	$1.85	1,188,076	No	4	P	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Common Warrants (right to buy)	Acquisiton	2023-09-25	422,732	$0.13	422,732	$3.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
422,732	2023-09-25		No	4	P	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Shares	124,344	Indirect	See footnote

Footnotes

These indirect holdings have been adjusted to give effect to the Company's 1-for-6 reverse stock split, effective July 10, 2023.
These securities are held directly by Shore Pharma LLC, of which Vimal Kavuru is the sole member.
Shares are held directly by Kottayil Grace Pharma LLC, of which Vimal Kavuru is a Manager. Mr. Kavuru is a Manager of Kottayil Grace Pharma LLC and shares voting and dispositive power with respect to the shares of Acasti Pharma Inc. directly held by Kottayil Grace Pharma LLC.
The Common Warrants reported herein contain an exercise limitation prohibiting the holder from exercising the Common Warrants until such time as the holder and certain other related parties, would not beneficially own after any such exercise more than 19.99% of the then issued and outstanding common shares of the Company (the "Blocker"). Due to the Blocker, the Common Warrants beneficially owned indirectly by the holder are only currently partially exercisable.
The Common Warrants will expire on the earlier of (i) the 60th day after the date of the acceptance by the U.S. Food and Drug Administration of a New Drug Application for the Company's product candidate GTX-104 or (ii) September 25, 2028.